(Last Updated on December 9, 2015 by Editor)
ZIMBABWE – The stock of Biotie Therapies Corporation Ads (NASDAQ:BITI) registered a decrease of 2.7% in short interest. BITI’s total short interest was 201,600 shares in December as published by FINRA. Its down 2.7% from 207,200 shares, reported previously. With 35,200 shares average volume, it will take short sellers 6 days to cover their BITI’s short positions. The short interest to Biotie Therapies Corporation Ads’s float is 3%. The stock is down 1.80% or $0.26 after the news, hitting $14.15 per share. About 3,710 shares traded hands. Biotie Therapies Oyj (ADR) (NASDAQ:BITI) has risen 6.00% since November 8, 2015 and is uptrending. It has outperformed by 6.59% the SP500.
More news for Biotie Therapies Oyj (ADR) (NASDAQ:BITI) were recently published by: Benzinga.com, which released: “Roth Puts A ‘Buy’ On Biotie…Firm Excited About ‘Best In Class Treatment’ For …” on July 07, 2015. Reuters.com‘s article titled: “Biotie Therapies Oyj announces start of tozadenant Phase 3 Study in Parkinson’s disease” and published on July 21, 2015 is yet another important article.
Biotie Therapies Oyj is a Finland-based drug development firm focused on developing products for neurodegenerative and psychiatric disorders. The company has a market cap of $195.79 million. The Company’s lead market product is Selincro , a therapeutic for alcohol dependence that is rolled out across Europe by its partner Lundbeck. It currently has negative earnings. The Company’s product pipeline includes tozadenant, a therapeutic for Parkinson’s disease that is in Phase Three development; and two additional compounds in Phase Two development that treat cognitive disorders, namely: SYN120, an orally administered compound therapeutic for Parkinson’s disease dementia, and BTT1023, a human monoclonal antibody targeting compound therapeutic for primary sclerosing cholangitis.